drugset / Trial / NCT06781125
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, dose-escalation and dose-expansion Phase I /II clinical study divided into Phase I and Phase II to evaluate the safety and tolerability of JCXH-211 combined with anti-PD-1 antibody in patients with malignant solid tumors.
Timeline
- Start
- 2026-03-18
- Primary completion
- 2028-03-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JCXH-211 | Other / unclassified | — | Other |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |